TELA Bio Inc. is a commercial stage medical technology company. It is focused on the designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices. TELA Bio Inc. is headquartered in Malvern, Pennsylvania.
| Revenue (Most Recent Fiscal Year) | $69.30M |
| Net Income (Most Recent Fiscal Year) | $-37.84M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.76 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.97 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -61.13% |
| Net Margin (Trailing 12 Months) | -61.00% |
| Return on Equity (Trailing 12 Months) | -402.45% |
| Return on Assets (Trailing 12 Months) | -62.73% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.40 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 2.28 |
| Inventory Turnover (Trailing 12 Months) | 1.74 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.46 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.25 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.33 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.41 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 39.56M |
| Free Float | 37.70M |
| Market Capitalization | $53.79M |
| Average Volume (Last 20 Days) | 0.15M |
| Beta (Past 60 Months) | 0.67 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 94.35% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |